Episode 3 - Talking Cardiovascular Disease Prevention: Emerging Strategies to Address Management Challenges in Dyslipidemia - Part 3: Dyslipidemia: Collaborative Care
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Episode 3 - Talking Cardiovascular Disease Prevention: Emerging Strategies to Address Management Challenges in Dyslipidemia - Part 3: Dyslipidemia: Collaborative Care
-
ナレーター：
-
著者：
このコンテンツについて
Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this podcast series, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).
Launch Date: February 16, 2024
Release Date: January 29, 2024
Expiration Date: January 31, 2025
FACULTY
R. Scott Wright, MD, FACC, FESC, FAHA
Professor of Medicine
Consultant in Cardiology
Mayo Clinic
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI
Director
Mount Sinai Fuster Heart Hospital
Dr. Valentin Fuster Professor of Cardiovascular Medicine
Icahn School of Medicine at Mount Sinai
This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.
https://www.practicepointcme.com/CMEHome/talking-cardiovascular-disease-prevention-emerging-strategies-to-address-management-challenges-in-dyslipidemia-1